Cyteir Therapeutics, Inc. (CYT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Lexington, MA, 미국. 현재 CEO는 Markus F. Renschler.
CYT 을(를) 보유 IPO 날짜 2021-06-18, 46 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $108.71M.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
